106 results about "Pulmonary edema" patented technology

The invention belongs to the technical field of medicines, and discloses application of baicalein in drugs related to the treatment effect of S protein and LPS induced acute lung injury. Specifically, the invention discloses an application of baicalein in preparation of drugs playing a protective role in treating pulmonary edema, inflammatory cell infiltration and cytokine storm caused by acute lung injury induced by S protein combined with LPS. Pharmacological experiments prove that baicalein has an anti-inflammatory effect in treatment of acute lung injury induced by S protein combined with LPS, and can improve pulmonary edema and promote lesion lung tissue repair.

The invention provides application of a probiotic composition in preparation of a medicine for preventing and / or treating pneumonia, and belongs to the technical field of biological medicine. The probiotic composition comprises sophora flower bud powder, a broccoli seed aqueous extract, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Research finds that the probiotic composition can significantly relieve pulmonary edema caused by pneumonia and also can significantly reduce the level of inflammatory factors in pneumonia, so that the probiotic composition has the effect of preventing and / or treating pneumonia, and more choices are provided for clinical drugs for preventing and / or treating pneumonia.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

The invention belongs to the technical field of medicine, particularly relates to application of isodan-leaf emodin in preparation of a CXCL10 inhibitor, and particularly relates to application of the isodan-leaf emodin in treatment of sepsis lung injury, and by establishing a sepsis lung injury model induced by cecum ligation puncture (CLP), the application of the isodan-leaf emodin in preparation of the CXCL10 inhibitor is established. It is proved that the polyphenol monomer drug isodan leaf emodin can significantly improve lung tissue pathological damage, reduce the level of inflammatory factors in lung tissue, inhibit oxidative stress reaction and improve the survival rate of a CLP model. Experiments show that the isodan leaf emodin with the dosage of 25 mg / kg can relieve pulmonary edema and inflammatory response by inhibiting secretion of CXCL10, and a new scheme is provided for treatment of sepsis-related lung injury.

The invention provides a nano-micelle responding to an inflammation microenvironment as well as a preparation method and application of the nano-micelle. According to the nano-micelle, polyethylene glycol (PEG)-poly L-glutamic acid (PLG) is grafted with 4-hydroxymethyl phenylboronic acid (PBA), and the drug loading capacity of a hydrophobic anti-inflammatory drug is improved based on a hydrophobic effect and a borate bond formed by the PBA and a 1, 3-diol or 1, 2-diol structure of dexamethasone, curcumin and luteolin. The nano-micelle (PPDex micelle) has reversible splitting and rapid release behaviors under an inflammatory condition (the ROS level is increased or the pH value is reduced). The nano-micelle has a proper particle size, can effectively relieve inflammatory cell infiltration and pulmonary edema in the lung of an acute lung injury (ALI) mouse after pulmonary administration, reduces pro-inflammatory cytokines in the lung, inhibits oxidative stress, promotes polarization of macrophages from pro-inflammatory M1 phenotype to anti-inflammatory M2 phenotype, and finally inhibits the progress of ALI. The invention provides a novel effective anti-inflammatory strategy.

The present invention relates to the field of medicines and relates to a fused five-membered and six-membered heterocyclic compound, a preparation method therefor, and a use thereof in the field of pharmaceuticals. Specifically, the present invention provides a compound having a structure represented by formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug thereof. The compound and a pharmaceutical composition thereof of the present invention can be used for preparing a medicament for treating HIF-2α-mediated related diseases, such as renal anemia, chronic kidney disease, chronic metabolic disease, neurodegenerative disease, infection, inflammatory disease, pulmonary edema, and acute respiratory distress syndrome.

A use of a sulfonamide compound represented by formula (I) or a pharmaceutical composition comprising same in the preparation of a drug for treating pulmonary edema.

The invention belongs to the field of respiratory system disease treatment, and provides application of a gymnadenia conopsea extract in preparation of a medicine for treating or preventing pulmonary edema. The embodiment of the invention proves that both the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract can effectively improve indexes such as pulmonary edema respiratory rate, minute ventilation volume, rising tidal volume, inspiration peak flow, expiration peak flow and the like, and improve arterial blood-gas indexes and inflammatory factor level in alveolar lavage fluid. The invention provides the application of the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract in the medicine for treating or preventing lung diseases, especially pulmonary edema for the first time, the traditional medicine gymnadenia conopsea is fully developed and utilized, and a safe and effective means is provided for treating the critical disease pulmonary edema.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

A method, system, and computer software product for evaluating a physiological state of a subject 22 with respect to a physiological condition, the method comprising obtaining at least one Hidden Markov Model 46 constructed from one or more reference speech samples 44 selected from the group consisting of: reference speech samples produced by the subject 22 at a first time while the physiological state of the subject was known, and reference speech samples produced by other subjects, the physiological condition being selected from the group consisting of: congestive heart failure, pulmonary edema, and pleural effusion, and the Hidden Markov Model including: multiple acoustic states 48 exhibited in the reference speech samples, the acoustic states being associated with respective local distance functions 50 such that, given any acoustic feature vector within a domain of the local distance functions, the local distance function of each acoustic state returns a local distance indicating a degree of correspondence between the given acoustic feature vector and the acoustic state, and allowed transitions 52 between the acoustic states; receiving at least one test speech sample 56 that was produced by the subject at a second time, while the physiological state of the subject was unknown; computing a plurality of test-sample feature vectors 60 that quantify acoustic features of different respective portions 58 of the test speech sample; based on the local distance functions and on the allowed transitions, mapping the test speech sample to a minimum-distance sequence of the acoustic states, by mapping the test-sample feature vectors to respective ones of the acoustic states such that a total distance between the test-sample feature vectors and the respective ones of the acoustic states is minimized, the total distance being based on respective local distances between the test-sample feature vectors and the respective ones of the acoustic states to which the test-sample feature vectors are mapped; and in response to mapping the test speech sample to the minimum-distance sequence of the acoustic states, generating an output indicating the physiological state of the subject at the second time.

The present invention discloses the preparation of patchouli flavonoid nanoliposomes and their application in inhalation treatment of acute lung injury, and relates to the field of medical technology. The patchouli flavonoid nanoliposomes provided by the present invention prepare patchouli flavonoids into a liposome dosage form, which has good stability and biocompatibility. The drug is administered to mice with acute lung injury, so that patchouli flavonoids can act on the mouse lungs in a targeted manner, reduce the expression of inflammatory factors such as IL-6, IL-1β and TNF-α in the mouse lungs to relieve inflammation, improve pulmonary edema, and reduce lung tissue damage, while increasing the levels of tight junction factors such as ZO-1, VE-Cadherin, E-Cadherin and Claudin5 to repair lung barrier damage. The present invention is expected to provide an effective strategy for the treatment of acute lung injury.

The invention discloses a vagus nerve electrical stimulation regulation method capable of relieving ARDS lung injury, and relates to the technical field of ARDS lung injury. In order to improve the therapeutic effect and prognosis of ARDS patients; comprising the following steps that 1, an ARDS animal model is established, and the animal model is constructed by instilling lipopolysaccharide (LPS) into the trachea; 2, after the ARDS model is established, separating and exposing the left vagus nerve of the animal; and 3, performing electrical stimulation on the left vagus nerve by using an electrical stimulation device, wherein the stimulation parameters comprise the voltage of 5V, the frequency of 5Hz and the pulse width of 2ms, and the stimulation lasts for 10 minutes. By implementing a vagus nerve electrical stimulation (VNS) regulation method, lung tissue pathological changes of an ARDS rat model can be remarkably improved, such as alveolar wall thickening, alveolar cavity stenosis and inflammatory cell infiltration, the lung injury score and the lung moisture-to-dry ratio are remarkably reduced, and the pulmonary edema condition is effectively relieved.

A deep learning system that detects and counts A-lines in lung images obtained with the VSI protocol, allowing untrained personnel to perform scans. By segmenting and counting A-lines, the system distinguishes between healthy lungs and conditions such as pneumonia or edema, without a specialist intervention. The Attention U-Net architecture improves accuracy, and A-line counting provides quantitative data for diagnostics. This approach aims to expand access to diagnostics, specially in resource-limited areas, offering a scalable solution for early detection of lung disease.

The invention belongs to the technical field of biological medicines, and particularly relates to a honeysuckle total extract inhalation solution as well as a preparation method and application thereof. According to the invention, the honeysuckle total extract with poor water solubility, phospholipid and chitosan are innovatively and directionally assembled into the chitosan-phospholipid nanoparticles with uniform structure, and the nanoparticles are prepared by adopting a microfluidic technology. The strategy significantly improves the water solubility and stability of the honeysuckle total extract, and successfully prepares an inhalation solution suitable for pulmonary administration based on the nanoparticle dispersion system. The obtained preparation has the characteristics of high physical stability and good bioavailability potential. The honeysuckle total extract inhalation solution provided by the invention can effectively relieve the pathological process of the pyotoxic pneumonia through multiple mechanisms of remarkably inhibiting lung inflammatory response, relieving pulmonary edema, protecting the structural integrity of pulmonary alveoli and the like. Especially, a high-dose group shows a curative effect superior to that of a positive control drug, and a good dose-effect relationship is combined, so that the preparation has remarkable development potential and clinical transformation prospect in treatment of the septic pneumonia.

A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.

Disclosed herein are stable solution, suspension and dry powder compositions, and methods for delivering stabilized biodegradable substances, including peptides and proteins, small molecules, and methods for delivering the dry powders in the treatment of lung disease. In particular, the compositions comprise vasoactive intestinal peptide for pulmonary inhalation to treat respiratory disorders and / or diseases in the lung, including, inflammation, acute and chronic lung injury and pulmonary edema.

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

The invention discloses a formula for tonifying kidney and qi and a prevention and treatment effect of a single medicine of the formula in plateau pulmonary edema. The invention provides application of a kidney-tonifying and qi-benefiting formula or a single medicine or an active ingredient thereof in preparation of a medicine for preventing and / or treating plateau pulmonary edema, the kidney-tonifying and qi-benefiting formula is a traditional Chinese medicinal material composed of herba epimedii, radix astragali and radix rehmanniae recen or an extract of the traditional Chinese medicinal material, the single medicine is herba epimedii, and the active ingredient is icariin. According to the present invention, the plateau pulmonary edema rat model is induced through low pressure and low oxygen, and the prevention and treatment effect of the kidney-tonifying qi-benefiting formula and the single drug or the active component thereof on the plateau pulmonary edema is verified in the animal model, such that the new treatment drug is provided for the clinical treatment of the plateau pulmonary edema, and the limitation of the existing treatment drug is hopefully overcome; good application prospects are realized.

The present invention involves recovering pulmonary inflammation, pulmonary edema or pulmonary capillary vasodilation symptoms caused by infection with viruses, particularly, coronavirus, and furthermore, has the effect of regenerating alveoli, and thus can effectively prevent, ameliorate or treat coronavirus infection or diseases caused by coronavirus infection.

The invention relates to application of a sulfonamide compound or a pharmaceutical composition containing the sulfonamide compound in preparation of a medicine for treating pulmonary edema. The medicine has a prominent curative effect on pulmonary edema by inhibiting NKCC1 targets of lungs and is high in safety, so that adverse effects such as electrolyte disorder caused by potent diuretics are reduced, and the medicine is a better new medicine for clinically treating pulmonary edema.

The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl urea derivatives, and further found that the compounds have an antagonistic activity against bradykinin B1 receptor, so that the compounds can be used as novel bradykinin B1 receptor antagonists and can be further used for treating or preventing related diseases caused by abnormal expression of the bradykinin B1 receptor. In particular, the present invention has recently found that N-tetrazolyl aryl urea derivatives have prevention or treatment effects on corona virus disease 2019, pulmonary edema, diabetes complications, allergic conjunctivitis, etc.

The invention provides application of SRSF1 in preparation of a medicine for preventing and / or treating ejection fraction reserved heart failure, and belongs to the technical field of biological medicine. The invention determines that the SRSF1 can be used as a key target for preparation of heart failure related medicines for preventing and / or treating ejection fraction retention. Animal model construction and cellular level experiments prove that SRSF1 participates in regulation of the pathological process of the disease. Experiments of constructing a model in an SRSF1 endothelial cell specific knockout mouse show that by inhibiting SRSF1 expression, symptoms such as diastolic dysfunction and hypertension can be improved, pulmonary edema can be relieved, and myocardial fibrosis and reconstitution can be inhibited. The abnormal glucose and lipid metabolism can be improved, and the endothelial-mesenchymal transition process can be inhibited. The invention opens up a new path for new drug screening, provides a new target and method for treatment of ejection fraction reserved heart failure, and has important medical significance and value.

This invention belongs to the field of biomedical technology and relates to a composition based on plant essential oils or active ingredients and its application in the preparation of drugs for the prevention and treatment of pulmonary edema. It comprises at least three plant essential oils or active ingredients; said plant essential oils or active ingredients have agonistic activity against aquaporins and agonistic activity against sodium-potassium ATPase. The composition and its special formulation provided by this invention not only have good preventive and therapeutic effects on pulmonary edema, but can also be applied to the prevention and treatment of related lung diseases such as hypersputum secretion, acute lung injury, acute respiratory distress syndrome, pulmonary fibrosis, and COPD.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of donkey-hide gelatin bone-strengthening oral liquid in prevention and treatment of plateau hypoxic polycythemia. The colla corii asini bone-strengthening oral liquid can be used for preparing medicines for reducing the number of red blood cells in the high altitude polycythemia, improving the form and function of the red blood cells in the high altitude polycythemia and improving pulmonary edema and encephaledema caused by the high altitude polycythemia. The colla corii asini bone-strengthening oral liquid is applied to prevention and treatment of the plateau hypoxic polycythemia, and the problems that at present, traditional Chinese medicine formulas for treating the plateau polycythemia clinically are few, and the plateau polycythemia resisting effect is poor can be solved.

The invention provides application of dragon's blood and active ingredients thereof in preparation of a medicine for treating heart failure, and belongs to the technical field of biological medicine. It is found for the first time that the dragon's blood can significantly improve the heart function of a heart failure model animal, reduce the level of a heart failure marker and relieve cardiac hypertrophy, cardiac pulmonary edema, myocarditis infiltration and fibrosis; core active components such as genistein and 3-hydroxycinnamic acid are screened and verified, wherein the genistein can reproduce the overall treatment effect of the dragon's blood. The invention also discloses that the core action mechanism of the composition is to promote macrophage VEGFC secretion, increase heart lymphatic vessel density and promote lymphatic vessel neogenesis, and a brand new natural drug candidate scheme and an intervention strategy are provided for heart failure treatment.

The invention relates to an application of a vasodilatation drug ferric nitrosyl chloride, which belongs to the field of chemistry and chemical engineering and medicine, and is characterized in that the molecular formula of the compound is Fe (NO) Cl3 or Fe (NO) Cl3. MH2O, m is equal to 1-3, and the compound is mainly used for emergency treatment and relieving of hypertensive emergencies and emergency blood pressure reduction. And acute respiratory distress syndrome caused by heart-lung related diseases such as pulmonary arterial hypertension, chronic obstructive pulmonary disease, plateau pulmonary edema, bronchial asthma, stroke and the like.

The invention belongs to the technical field of medicines, and particularly relates to application of Northyriol in preparation of a medicine for treating inflammatory diseases. According to the present invention, the Northoriol and the NLRP3 inflammasome have the binding capacity, and the Northoriol can inhibit the NLRP3 expression so as to reduce the IL-1beta gene expression at the downstream of the NLRP3 expression, such that the IL-1beta secretion in the mouse bone marrow macrophages induced by the LPS and the Nigonicin can be significantly reduced in the concentration-dependent manner; in an ulcerative colitis model, Norathyriol effectively reduces a DAI score, relieves weight loss, colon shortening and intestinal inflammation, and remarkably improves pathological injuries of colon tissues, including inflammatory cell infiltration, epithelium shedding and crypt structure destruction. Besides, the Northyriol also has a remarkable treatment effect on a pneumonia model, relieves pulmonary edema and pulmonary alveolar structure damage, improves weight loss and T cell differentiation imbalance caused by H1N1 infection, and improves organ indexes, so that the Northyriol has dual effects of relieving lung inflammation and regulating immune functions.

The invention relates to application of tectoridin in preparation of a medicine for treating radiation-induced lung injury. According to the invention, the influence of tectoridin on radiation-induced lung injury is researched by constructing a C57BL / 6 mouse radiation-induced lung injury model; research results prove that the exogenous irisin can relieve alveolar interstitial thickening, hyperemia, pulmonary edema, alveolar collapse, airway wall thickening, airway cavity narrowing and increase of collagen deposition around the airway caused by radiation; besides, the tectoridin obviously reduces lung tissue inflammatory factor synthesis and release, inflammatory cell infiltration and oxidative stress caused by radiation, and obviously reduces lung tissue fibrosis and lung tissue function barrier caused by radiation, the effect of the tectoridin in resisting radiation-induced lung injury is further proved, research and application of the tectoridin are broadened, and the application range of the tectoridin in resisting radiation-induced lung injury is widened. Meanwhile, a new target spot and a new visual field are provided for treating the radiation-induced lung injury.